RxDoctor Payments Data

John Chorba, MD

Cardiovascular Disease · Boston, MANPI 1538364138

Payments from drug & device makers

$111,662in general payments, 2019–2025

Across 11 payments — averaging $10,151 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$75K
  • Eko Health, Inc.$22K
  • Pfizer$15K

What the payments were for

  • Consulting fees$21,13997%
  • Speaking & faculty fees$2501%
  • Food & beverage$320%
  • Other$4292%

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis4$74,844
Eko Health, Inc.6$21,818
Pfizer1$15,000

How this compares

$111,662 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$35,357
Medicare patients
249
Services billed
400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium12$53

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →